医疗ETF 09:00事件流｜2026年9月10日（18条）

[ { "event_id": "sec-us-20260909-tyra-surf302-orr79", "title": "Tyra 公布 SURF302 初步结果并锁定剂量", "event_time_utc": "2026-09-09T07:10:06Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T07:10:06Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 90, "horizon": "weeks", "raw_facts": "Tyra Biosciences（Nasdaq: TYRA）8-K 公告 SURF302 二期初步结果：口服 dabogratinib 在 FGFR3 改变的低级别中危非肌层浸润性膀胱癌中，60 mg QD 队列可评价患者 3 个月 ORR 为 79%（11/14），确定 60 mg QD 为支持注册性辅助治疗策略剂量；44 例中 3 级 TRAE 共 2 例（4.5%），均发生在 50 mg 组，60 mg 组无。", "transmission_chain": "Tyra 披露 SURF302 初步结果并锁定 60 mg QD 剂量→FGFR3 膀胱癌管线获得临床验证→后续注册性试验推进。", "invalidation_conditions": "公司更正 ORR 数据或安全性结论；后续随访疗效大幅回落。", "source_urls": [ "[https://www.[sec.gov/Archives/edgar/data/1863127/000119312526385886/d167841d8k.htm](https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/d167841d8k.htm)](https://sec.gov/Archives/edgar/data/1863127/000119312526385886/d167841d8k.htm](https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/d167841d8k.htm))" ], "source_tier": "A" }, { "event_id": "sec-us-20260909-opus-best1-typec", "title": "Opus 视网膜基因疗法获阳性数据并对齐终点", "event_time_utc": "2026-09-09T07:30:47Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T07:30:47Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 88, "horizon": "weeks", "raw_facts": "Opus Genetics（Nasdaq: IRD）公布 OPGx-BEST1 低剂量队列 1（5 例）3/6 个月结果：5/5 例视功能改善（BCVA 改善 3/5、LLVA 改善 2/5、微视野改善 3/4），4/5 例结构改善；完成 FDA Type C 会议，FDA 认可微视野较基线改善≥3 分贝作为潜在关键终点；潜在三期计划 2027 年给药。", "transmission_chain": "OPGx-BEST1 早期临床阳性且 FDA 认可微视野终点→视网膜病基因治疗三期注册路径明确→后续临床与给药节奏决定管线价值。", "invalidation_conditions": "FDA 会议记录更正；后续队列未能复制视功能改善；三期申报推迟。", "source_urls": [ "[https://www.[sec.gov/Archives/edgar/data/1228627/000114036126035979/ef20081753_ex99-1.htm](https://www.sec.gov/Archives/edgar/data/1228627/000114036126035979/ef20081753_ex99-1.htm)](https://sec.gov/Archives/edgar/data/1228627/000114036126035979/ef20081753_ex99-1.htm](https://www.sec.gov/Archives/edgar/data/1228627/000114036126035979/ef20081753_ex99-1.htm))" ], "source_tier": "A" }, { "event_id": "sec-us-20260909-pyxis-micvo-phase1", "title": "Pyxis 更新 MICVO 头颈鳞癌一期数据", "event_time_utc": "2026-09-09T07:34:45Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T07:34:45Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 90, "horizon": "weeks", "raw_facts": "Pyxis Oncology（Nasdaq: PYXS）公布 MICVO 全球一期在 2L+头颈鳞癌更新数据（N=33 可评价）：确认 ORR 为 36%（12/33），DCR 为 94%（31/33），中位 PFS 为 6.2 个月（95% CI 4.8–8.8），12 个月 OS 概率为 79%（95% CI 58.1–90.3）；计划 2027 年中启动随机三期 Headliner 研究。", "transmission_chain": "首创 EDB+FN ADC 公布一期疗效与生存数据→头颈鳞癌后线治疗展现竞争力→三期试验启动与后续读出决定估值。", "invalidation_conditions": "公司更正 cORR、DCR 或 mPFS 数据；FDA/EMA 对三期设计提出实质异议。", "source_urls": [ "[https://www.[sec.gov/Archives/edgar/data/1782223/000119312526385901/pyxs-ex99_1.htm](https://www.sec.gov/Archives/edgar/data/1782223/000119312526385901/pyxs-ex99_1.htm)](https://sec.gov/Archives/edgar/data/1782223/000119312526385901/pyxs-ex99_1.htm](https://www.sec.gov/Archives/edgar/data/1782223/000119312526385901/pyxs-ex99_1.htm))" ], "source_tier": "A" }, { "event_id": "cninfo-cn-20260909-dongcheng-bemiparin-nda", "title": "东诚药业贝米肝素钠上市申请获 NMPA 受理", "event_time_utc": "2026-09-09T00:00:00Z", "event_time_quality": "day_only", "published_at_utc": "2026-09-09T08:00:00Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 90, "horizon": "weeks", "raw_facts": "东诚药业（002675.SZ）公告编号 2026-062：子公司烟台东诚北方制药收到国家药监局《受理通知书》，贝米肝素钠注射液（0.2ml:3500AⅩaIU）上市许可申请获受理，受理号 CYHS2602247。贝米肝素钠为超低分子肝素，国内仅原研上市、无仿制药上市；魔熵医药数据显示 2025 年国内全终端医院销售额为 3 亿元。", "transmission_chain": "超低分子肝素首仿申报获 NMPA 受理→东诚药业抗凝血产品管线扩充→进入审评排队，后续取决于获批进度。", "invalidation_conditions": "NMPA 不予受理或要求补充重大资料；公司更正受理号或销售数据。", "source_urls": [ "https://static.cninfo.com.cn/finalpage/2026-09-10/1225555469.PDF" ], "source_tier": "A" }, { "event_id": "cninfo-cn-20260909-hengrui-retepatide-nda", "title": "恒瑞瑞普泊肽 NDA 获受理且 III 期优于司美", "event_time_utc": "2026-09-09T00:00:00Z", "event_time_quality": "day_only", "published_at_utc": "2026-09-09T08:00:00Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 2 }, "confidence": 92, "horizon": "weeks", "raw_facts": "恒瑞医药（600276.SH）公告临 2026-142：子公司福建盛迪医药瑞普泊肽注射液（GLP-1/GIP 双激动剂）上市申请获 NMPA 受理（CXHS2600128、CXHS2600129），拟用于成人 2 型糖尿病血糖控制。PRIME-2 关键 III 期（884 例）头对头对比司美格鲁肽注射液 1 mg（HbA1c 降幅 2.29%），第 36 周瑞普泊肽 4 mg 组 HbA1c 降幅 2.78%、2 mg 组 2.34%，主要终点达非劣效，4 mg 组达优效（单侧 p<0.0001）；累计研发投入约 74,590 万元。", "transmission_chain": "自研 GLP-1/GIP 申报上市且头对头司美格鲁肽优效→恒瑞代谢管线形成核心商业化预期→进入上市审评链。", "invalidation_conditions": "NMPA 退审或要求重大补充试验；公司更正 PRIME-2 统计学优效结论或研发投入数字。", "source_urls": [ "https://static.cninfo.com.cn/finalpage/2026-09-10/1225555692.PDF" ], "source_tier": "A" }, { "event_id": "cninfo-cn-20260909-puluo-cefditoren-pivoxil", "title": "普洛药业头孢托仑匹酯化学原料药获批上市", "event_time_utc": "2026-09-09T00:00:00Z", "event_time_quality": "day_only", "published_at_utc": "2026-09-09T08:00:00Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 90, "horizon": "weeks", "raw_facts": "普洛药业（000739.SZ）公告编号 2026-83：子公司浙江普洛得邦制药收到国家药监局签发的头孢托仑匹酯《化学原料药上市申请批准通知书》（编号 2026YS00839，原料药登记号 Y20250000349，包装规格 5kg/桶、10kg/桶、25kg/桶）；产品具备国内销售资格，拓宽抗感染原料药管线。", "transmission_chain": "头孢托仑匹酯原料药获批注册→普洛药业具备国内合法销售资格→原料药做精战略与产能利用率提升。", "invalidation_conditions": "批准通知书被药监撤销或更正；原料药文号被吊销或限制生产。", "source_urls": [ "https://static.cninfo.com.cn/finalpage/2026-09-10/1225555510.PDF" ], "source_tier": "A" }, { "event_id": "cninfo-cn-20260909-baili-blb01d1-panku-lung08", "title": "百利天恒 BL-B01D1 肺癌 III 期首例入组", "event_time_utc": "2026-09-10T00:00:00Z", "event_time_quality": "day_only", "published_at_utc": "2026-09-09T08:00:00Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 90, "horizon": "weeks", "raw_facts": "百利天恒（688506.SH）公告编号 2026-065：自研 EGFR×HER3 双抗 ADC 宜泽康（BL-B01D1）联合奥希替尼对比奥希替尼单药用于不可切除 EGFR 突变型 III 期 NSCLC 同步放化疗后维持治疗的 III 期随机对照试验（PANKU-Lung08）完成首例受试者入组；截至公告日该产品全球开展超 45 项临床试验，其中 III 期（含 II/III 期）20 项。", "transmission_chain": "首创双抗 ADC 进入同步放化疗后维持治疗大适应症 III 期→百利天恒在研 III 期管线推进→长期商业化空间验证。", "invalidation_conditions": "临床试验暂停或方案重大修正；公司更正入组状态或试验设计。", "source_urls": [ "https://static.cninfo.com.cn/finalpage/2026-09-10/1225555454.PDF" ], "source_tier": "A" }, { "event_id": "cninfo-cn-20260909-dizhe-birelentinib-dlbcl", "title": "迪哲医药比瑞替尼淋巴瘤二期获专业期刊发表", "event_time_utc": "2026-09-10T00:00:00Z", "event_time_quality": "day_only", "published_at_utc": "2026-09-09T08:00:00Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 88, "horizon": "weeks", "raw_facts": "迪哲医药（688192.SH）公告编号 2026-058：自研 LYN/BTK 双靶点抑制剂比瑞替尼治疗复发/难治弥漫大 B 细胞淋巴瘤（r/r DLBCL）II 期 TAI-SHAN9 结果发表于《Blood Cancer Journal》（IF 13.8）：在既往接受过 1-5 线治疗患者中，整体 ORR 47.6%、CRR 31.0%，获得完全缓解者 mDoR 尚未达到且最长 DoR 超 9.3 个月，未报告与药物相关的大出血或房颤。", "transmission_chain": "自研靶向药 II 期临床结果在权威血液肿瘤期刊发表→疗效与安全性获得同行评审认可→后续关键试验及注册确定性提升。", "invalidation_conditions": "期刊撤稿或更正关键数据；后续试验未能重现 ORR 与安全性指标。", "source_urls": [ "https://static.cninfo.com.cn/finalpage/2026-09-10/1225554898.PDF" ], "source_tier": "A" }, { "event_id": "sec-us-20260909-tenax-level-endpoint", "title": "Tenax 披露 LEVEL 试验主要终点未达显著", "event_time_utc": "2026-09-09T08:00:12Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T08:00:12Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": -1 }, "confidence": 90, "horizon": "days", "raw_facts": "Tenax Therapeutics（Nasdaq: TENX）通过 8-K/EX-99.1 公布 LEVEL 试验完整结果：TNX-103 治疗 PH-HFpEF 的主要终点未达到统计学显著性；12 周盲态评估显示心脏壁应力指标 NT-proBNP 下降约 49%，肺动脉压（RVSP）下降 3.5 mmHg；公司正基于基线受损更重患者的运动获益进行亚组评估。", "transmission_chain": "主要临床试验终点未达显著→心血管罕见病管线商业化概率受挫→公司转向亚组分析以寻求后续路径。", "invalidation_conditions": "公司更正主要终点统计学结论；FDA 出具明确监管意见改变开发定性。", "source_urls": [ "[https://www.[sec.gov/Archives/edgar/data/34956/000119312526385910/d43255dex991.htm](https://www.sec.gov/Archives/edgar/data/34956/000119312526385910/d43255dex991.htm)](https://sec.gov/Archives/edgar/data/34956/000119312526385910/d43255dex991.htm](https://www.sec.gov/Archives/edgar/data/34956/000119312526385910/d43255dex991.htm))" ], "source_tier": "A" }, { "event_id": "nmpa-cn-20260909-qx-pjzmwsd-54", "title": "国家药监局送达 54 件医疗器械批准证明文件", "event_time_utc": null, "event_time_quality": "day_only", "published_at_utc": "2026-09-09T08:03:00Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 0 }, "confidence": 85, "horizon": "days", "raw_facts": "国家药品监督管理局政务服务门户于北京时间 2026-09-09 16:03 发布《2026 年 09 月 09 日医疗器械批准证明文件送达信息》，共涉及 54 个医疗器械产品；批准日期分布在 2026-9-4（35 条）与 2026-9-7（19 条），以延续与变更类注册为主；涉及广州万孚生物乙肝抗原检测试剂、稳健平安无菌胰岛素注射器、深圳半岛医疗射频治疗仪等境内外上市企业批件。", "transmission_chain": "NMPA 集中公示 54 项医疗器械批准证明文件送达→企业合规取件进入上市/生产执行阶段→日常器械注册审批节奏稳定。", "invalidation_conditions": "NMPA 撤销或更正该批次送达清单；产品批件信息被证明早于本窗口。", "source_urls": [ "https://www.nmpa.gov.cn/zwfw/sdxx/sdxxylqx/qxpjfb/20260909160633105.html" ], "source_tier": "A" }, { "event_id": "dart-kr-20260909-voronoi-vrn110755-withdrawal", "title": "Voronoi 自愿撤回 VRN110755 加拿大临床计划", "event_time_utc": "2026-09-09T08:08:00Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T08:08:00Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": -1 }, "confidence": 90, "horizon": "days", "raw_facts": "韩国上市公司보로노이（Voronoi）通过 DART 公告（编号 20260909900586）：VRN110755（EGFR 突变 NSCLC，计划入组 391 例，申请号 202300849）在加拿大卫生部（Health Canada）的 1/2 期临床试验计划申请被撤回，公司于同日收到 CRO 转交的撤回通知；同日韩国交易所对该事项发出更正要求，公司于 17:29 KST 提交更正申请。", "transmission_chain": "海外临床计划被撤回并收到交易所更正要求→EGFR 管线海外临床节奏受阻→公司调整申报方案并重新备案。", "invalidation_conditions": "公司更正撤回原因仅为纯行政技术性调整；加拿大卫生部恢复审评程序。", "source_urls": [ "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260909900586" ], "source_tier": "A" }, { "event_id": "nmpa-cn-20260909-yp-pjzmwsd-38", "title": "国家药监局送达 38 件药品批准证明文件", "event_time_utc": null, "event_time_quality": "day_only", "published_at_utc": "2026-09-09T08:14:00Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 0 }, "confidence": 85, "horizon": "days", "raw_facts": "国家药品监督管理局政务服务门户于北京时间 2026-09-09 16:14 发布《2026 年 09 月 09 日药品批准证明文件送达信息》，共 38 条记录；其中 5 条核发新批准文号（国药准字 H20269223 至 H20269227，涉及依非韦伦片、注射用氨苄西林钠、玻璃酸钠滴眼液等）；其余以补充申请与再注册为主，涉及甘李药业门冬胰岛素、复宏瑞霖斯鲁利单抗等品种。", "transmission_chain": "NMPA 常规送达 38 件药品批件→企业完成批件签领进入流通或变更实施→反映行业常规审评审批吞吐量。", "invalidation_conditions": "NMPA 撤销或更正该批次文号；官方公示被核实不在窗口内。", "source_urls": [ "https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20260909161655149.html" ], "source_tier": "A" }, { "event_id": "nmpa-cn-20260909-yp-tzj-23", "title": "国家药监局送达 23 件药品通知件", "event_time_utc": null, "event_time_quality": "day_only", "published_at_utc": "2026-09-09T08:17:00Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 0 }, "confidence": 85, "horizon": "days", "raw_facts": "国家药品监督管理局政务服务门户于北京时间 2026-09-09 16:17 发布《2026 年 09 月 09 日药品通知件送达信息》，共 23 条记录；签发日期以 2026 年 9 月 8 日为主（16 条），另有 9 月 4 日 4 条等；通知件为审评审批过程中的行政通知文书，未披露批准与否结论；涉及兴齐眼药妥布霉素滴眼液、科伦制药环孢素口服溶液等受理号主体。", "transmission_chain": "NMPA 送达药品审评过程通知件→申报企业按要求完成材料补充或后续流程办理→不直接改变产品批准状态。", "invalidation_conditions": "NMPA 撤销通知件送达信息；企业公布正式审评结论。", "source_urls": [ "https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20260909161959119.html" ], "source_tier": "A" }, { "event_id": "sec-us-20260909-xeris-xp8121-phase3", "title": "Xeris 公布皮下左甲状腺素三期试验设计", "event_time_utc": "2026-09-09T08:33:41Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T08:33:41Z", "event_type": "clinical_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 90, "horizon": "weeks", "raw_facts": "Xeris Biopharma（Nasdaq: XERS）通过 8-K/EX-99.2 披露 XP-8121（每周一次皮下左甲状腺素）三期 Cornerstone 设计：入组 500 名控制良好的甲减患者，开展 54 周 1:1 随机对照，主要终点为第 48 与 54 周 TSH 维持正常比例，非劣效界值 15%；研究拟于 2026 年底前启动，顶线预计 2028 年底；公司预期该产品峰值净收入为 10–30 亿美元。", "transmission_chain": "长效甲状腺激素替代疗法三期注册方案确定→年底前启动 500 例随机对照试验→公司给出 10-30 亿美元峰值收入指引。", "invalidation_conditions": "FDA 要求修改三期终点或样本量；试验启动延迟或公司下修峰值指引。", "source_urls": [ "[https://www.[sec.gov/Archives/edgar/data/1867096/000186709626000077/exh992xp-8121event.htm](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/exh992xp-8121event.htm)](https://sec.gov/Archives/edgar/data/1867096/000186709626000077/exh992xp-8121event.htm](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/exh992xp-8121event.htm))" ], "source_tier": "A" }, { "event_id": "sec-us-20260909-inbs-510k-codeine", "title": "INBS 向 FDA 提交可待因指纹检测 510k 申请", "event_time_utc": "2026-09-09T08:50:25Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T08:50:25Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 88, "horizon": "weeks", "raw_facts": "Intelligent Bio Solutions（Nasdaq: INBS）通过 8-K/EX-99.1 宣布向 FDA 提交 510(k)上市前通知，申请 Intelligent Fingerprinting 药物筛查系统用于检测阿片类可待因；方法学研究显示准确率>98%、灵敏度>94%、特异性 100%，样本经 LC-MS/MS 验证，完成超 1600 次精密度测定。", "transmission_chain": "新型无创指纹药物筛查系统完成 510(k)递交→进入 FDA 医疗器械实质审评阶段→后续取决于 FDA 许可决定与商业化准入。", "invalidation_conditions": "FDA 拒绝受理或要求补充重大临床证据；510(k)被撤回或否决。", "source_urls": [ "[https://www.[sec.gov/Archives/edgar/data/1725430/000149315226041901/ex99-1.htm](https://www.sec.gov/Archives/edgar/data/1725430/000149315226041901/ex99-1.htm)](https://sec.gov/Archives/edgar/data/1725430/000149315226041901/ex99-1.htm](https://www.sec.gov/Archives/edgar/data/1725430/000149315226041901/ex99-1.htm))" ], "source_tier": "A" }, { "event_id": "yicai-cn-20260909-bcg-biosimilar-market-forecast", "title": "第一财经转述 BCG 预计 2035 生物类似药破 2400 亿", "event_time_utc": "2026-09-09T11:42:32Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T11:42:32Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 80, "horizon": "weeks", "raw_facts": "第一财经原创报道：波士顿咨询（BCG）测算未来十年全球 118 款生物药即将失去专利或独占权，开放市场价值有望达 2340 亿美元；预计 2035 年全球生物类似药市场规模将突破 2400 亿美元；在欧美市场，生物药专利到期 4 年后生物类似药可夺约 70%份额；麦肯锡研究显示立项到获批平均成功率 36.7%；复宏汉霖 2026 年上半年生物类似药销售收入 21.55 亿元、占比 60.06%，净利润 4.30 亿元（同比+10.3%）。", "transmission_chain": "权威咨询机构发布生物类似药放量测算数据→第一财经医药条线定量转述→国内生物类似药研发与出海龙头长期放量预期强化。", "invalidation_conditions": "第一财经撤稿或更正 BCG 测算数据；后续集采降价幅度超预期压制放量金额。", "source_urls": [ "[https://www.[yicai.com/news/103358218.html](https://www.yicai.com/news/103358218.html)](https://yicai.com/news/103358218.html](https://www.yicai.com/news/103358218.html))" ], "source_tier": "B" }, { "event_id": "sec-us-20260909-cooper-q3-results", "title": "Cooper 公布 Q3 业绩：营收 10.66 亿美元增 1%", "event_time_utc": "2026-09-09T16:34:31Z", "event_time_quality": "exact", "published_at_utc": "2026-09-09T16:34:31Z", "event_type": "sales_data", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 0 }, "confidence": 95, "horizon": "days", "raw_facts": "CooperCompanies（Nasdaq: COO）通过 8-K 披露截至 2026-07-31 的 2026 财年第三财季业绩：营收 10.66 亿美元，同比增 1%；GAAP 摊薄 EPS 2.24 美元（含一次性税收收益 3.072 亿美元），Non-GAAP 摊薄 EPS 1.15 美元（同比增 4%）；自由现金流 2.73 亿美元（同比增 66%）；毛利率 67%；CooperVision 收入 7.170 亿美元持平，公司主动下调美国渠道库存将继续影响第四季度。", "transmission_chain": "全球隐形眼镜及眼科医疗器械龙头发布季度业绩→自由现金流强劲但渠道去库存压制短期营收增速→反映海外眼科器械消费复苏节奏。", "invalidation_conditions": "公司更正财务报告数字；后续审计调整导致重大业绩变动。", "source_urls": [ "[https://www.[sec.gov/Archives/edgar/data/711404/000162828026061155/cooperq32026pressrelease.htm](https://www.sec.gov/Archives/edgar/data/711404/000162828026061155/cooperq32026pressrelease.htm)](https://sec.gov/Archives/edgar/data/711404/000162828026061155/cooperq32026pressrelease.htm](https://www.sec.gov/Archives/edgar/data/711404/000162828026061155/cooperq32026pressrelease.htm))" ], "source_tier": "A" }, { "event_id": "fda-us-20260909-sevabertinib-approval", "title": "FDA 加速批准 sevabertinib 一线非鳞 NSCLC", "event_time_utc": "2026-09-09T00:00:00Z", "event_time_quality": "day_only", "published_at_utc": "2026-09-09T22:00:00Z", "event_type": "drug_approval", "asset_keys": [ "MEDICAL" ], "direction_score": { "MEDICAL": 1 }, "confidence": 95, "horizon": "weeks", "raw_facts": "美国 FDA 于 2026-09-09 宣布加速批准 sevabertinib（商品名 Hyrnuo，拜耳）用于携带 HER2 酪氨酸激酶结构域激活突变的局部晚期或转移性非鳞状非小细胞肺癌一线成人患者；SOHO-01 研究中 69 例一线患者经 BICR 评估 ORR 为 75%（95% CI 64–85），73%的缓解者 DOR≥6 个月，38%缓解者 DOR≥12 个月；推荐剂量为 20 mg 口服每日两次。", "transmission_chain": "FDA 批准靶向药一线适应症扩展→HER2 突变肺癌患者获得首款口服一线靶向选择→推动同靶点 ADC 及小分子竞品研发与审评预期。", "invalidation_conditions": "FDA 撤回加速批准或修改说明书；验证性试验未能证实临床获益。", "source_urls": [ "[https://www.[fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small)](https://fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small))" ], "source_tier": "A" } ]